×
About 500 results

ALLMedicine™ T Cell Lymphomas Center

Research & Reviews  174 results

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
https://clinicaltrials.gov/ct2/show/NCT05430971

Jan 26th, 2023 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy. In 2008, it was recognized by the WHO as a distinct entity and separately listed in the group of acute myeloid leukemias and related precursor neoplasms. The fi...

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05313243

Jan 12th, 2023 - CD30- Positive Peripheral T cell (PTCL) and Cutaneous T cell Lymphomas (CTCL): T-cell Non-Hodgkin Lymphoma (NHL) includes a clinically heterogeneous group of mature T-cell lymphomas accounting for 10-12% of all NHL. Peripheral T- cell Lymphoma (PT...

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
https://clinicaltrials.gov/ct2/show/NCT03586999

Jan 9th, 2023 - Patients in this study will receive nivolumab in combination with the standard of care dose-adjusted EPOCH (etoposide, prednisone, vincristine, doxorubicin, cyclophosphamide) for six 21 day cycles. Patients will then have an autologous stem cell t...

Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a...
https://doi.org/10.1182/bloodadvances.2022008524
Blood Advances; Damaj G, Aubrais R et. al.

Dec 9th, 2022 - Patients with Relapsed or Refractory (R/R) Peripheral T cell Lymphomas (PTCL) have a poor prognosis. Bendamustine (B) and Brentuximab Vedotin (Bv) have shown interesting results in this setting. However, little information is available about their...

The cross-talk between miRNAs and JAK/STAT pathway in cutaneous T cell lymphoma: Emphas...
https://doi.org/10.1016/j.semcdb.2022.09.015
Seminars in Cell & Developmental Biology; Patil K, Sher G et. al.

Oct 11th, 2022 - Mycosis Fungoides (MF) and Sézary Syndrome (SS) belong to a wide spectrum of T cell lymphoproliferative disorders collectively termed cutaneous T cell lymphomas (CTCL). CTCLs represent an archetype of heterogeneous and dynamically variable lymphop...

see more →

Clinicaltrials.gov  19 results

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
https://clinicaltrials.gov/ct2/show/NCT05430971

Jan 26th, 2023 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy. In 2008, it was recognized by the WHO as a distinct entity and separately listed in the group of acute myeloid leukemias and related precursor neoplasms. The fi...

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05313243

Jan 12th, 2023 - CD30- Positive Peripheral T cell (PTCL) and Cutaneous T cell Lymphomas (CTCL): T-cell Non-Hodgkin Lymphoma (NHL) includes a clinically heterogeneous group of mature T-cell lymphomas accounting for 10-12% of all NHL. Peripheral T- cell Lymphoma (PT...

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
https://clinicaltrials.gov/ct2/show/NCT03586999

Jan 9th, 2023 - Patients in this study will receive nivolumab in combination with the standard of care dose-adjusted EPOCH (etoposide, prednisone, vincristine, doxorubicin, cyclophosphamide) for six 21 day cycles. Patients will then have an autologous stem cell t...

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT03905135

Sep 13th, 2022 - Background: Mature T-cell cancers are a phenotypically heterogeneous group of malignancies which constitute 10-15% of all non-Hodgkin lymphomas (NHL). Patients with relapsed/refractory T cell lymphomas have limited therapeutic options, making new ...

APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05186012

Jul 29th, 2022 - This is an open-label, multi-center Phase Ib/II study of safety, PK, PD and efficacy of APG-1252 as a single agent in relapsed/refractory NHL or in combination with chidamide in relapsed/refractory peripheral T cell lymphomas (PTCL) patients. The ...

see more →

News  7 results

Novel Treatment Strategies for PTCL
https://www.onclive.com/view/novel-treatment-strategies-for-ptcl

Apr 2nd, 2021 - For High-Definition, Click Multiple clinical trials are exploring romidepsin as a treatment for patients with peripheral T-cell lymphomas (PTCL), explains Myron Czuczman, MD. A phase III study will look at romidepsin plus CHOP versus CHOP alone ...

Novel Agents, Combinations on Horizon for MCL
https://www.onclive.com/view/novel-agents-combinations-on-horizon-for-mcl

Dec 20th, 2020 - Bijal D. Shah, MD The completion of pivotal clinical trials and the FDA approval of new therapies have dramatically changed the treatment paradigm for patients with mantle cell lymphoma (MCL). This evolution was initiated by the accelerated appro...

Dr. Anas Younes Discusses IPI-145 and ABT-199
https://www.onclive.com/view/dr-younes-on-ipi-145-and-abt-199-in-lymphoid-malignancies

Dec 20th, 2020 - Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the clinical value of IPI-145 and ABT-199 as treatment options for patients with lymphoid malignancies. IPI-145 is a PI3K-delta and gamma inhibitor that a...

The MEK Junction: Protein Presents a Ripe Target for Inhibitors
https://www.onclive.com/view/the-mek-junction-protein-presents-a-ripe-target-for-inhibitors

Dec 5th, 2020 - Role of MEK in Signaling Pathways The diagram shows MEK’s position among the key processes of both the MAPK/ERK and the PI3K/Akt/mTOR pathways. Though located far downstream of the extracellular trigger that initiates its signaling pat...

Dr. Gascoyne on Predictive Biomarker Research in Lymphomas
https://www.onclive.com/view/dr-gascoyne-on-predictive-biomarker-research-in-lymphomas

Dec 4th, 2020 - Randy Gascoyne, MD, research director, Centre for Lymphoid Cancers at the BC Cancer Agency, discusses the growth of predictive biomarker research in follicular lymphoma and other malignancies. Pertaining to follicular lymphoma, Gascoyne says ther...

see more →